Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers